Categories
Sport

2024 NFL free company reside tracker: Up to date signings, trades, rumors

NFL free agency is here. Teams are now allowed to negotiate with free agents, and players can officially be signed by new teams Wednesday at 4 p.m. ET with the start of the new league year.

There were several franchise tags handed out before the deadline last week, and we’ve already seen several signings, re-signings and extensions doled out, including a blockbuster $180 million deal for quarterback Kirk Cousins in Atlanta, $100 million extension for quarterback Baker Mayfield to stay in Tampa Bay, a big deal for defensive tackle Christian Wilkins with Las Vegas and a major re-up in Kansas City for defensive tackle Chris Jones. There have also been a few trades, including the Giants bringing in Brian Burns, the Browns adding wide receiver Jerry Jeudy and the Jaguars acquiring quarterback Mac Jones.

We’re tracking all of the live action, including signings, notable trades, cap-saving releases and more. Here are all the latest moves, rumors and news.

coverage:
Grading biggest deals | Top 100 free agents
Barnwell’s FA tiers | Making sense of QB deals

Latest free agency and trade market updates

Categories
Entertainment

Olympic Gymnast Nastia Liukin Shares Recommendation for Workforce USA Earlier than Paris

She was part of the gold-winning teams at both the 2012 London Games and the 2016 Rio de Janeiro Games. She also won gold in the gymnastics all-around in 2016, becoming the first African American to do so. 

Douglas stepped away from the mat after the Rio Games and has become a prominent TV and media fixture. She published her 2012 memoir Grace, Gold, and Glory, was the subject of the 2014 Lifetime movie The Gabby Douglas Story and starred with her family in the Oxygen unscripted series Douglas Family Gold.

Other TV appearances include Kickin It and Undercover Boss, along with winning The Masked Dancer in 2020.

In 2024, she announced her comeback to the sport, sharing her hopes to compete in the 2024 Paris Olympics.

Categories
Science

Black Holes Want Refreshing Chilly Gasoline to Maintain Rising

The Universe is filled with supermassive black holes. Almost every galaxy in the cosmos has one, and they are the most well-studied black holes by astronomers. But one thing we still don’t understand is just how they grew so massive so quickly. To answer that, astronomers have to identify lots of black holes in the early Universe, and since they are typically found in merging galaxies, that means astronomers have to identify early galaxies accurately. By hand. But thanks to the power of machine learning, that’s changing.

With the power of current and future sky surveys, the challenge of astronomy is less about capturing the right data and more about filtering out the right data from the vast trove we gather. It takes a tremendous amount of skill to distinguish a true merging galaxy from an irregular galaxy or two independent galaxies that just happen to be seen in the same patch of sky. People can be trained to do it well, but the need for skilled identifiers far surpasses the number of skilled people. One way to overcome this is to allow volunteers to fill the gap. In general, their identifications won’t be as accurate as the professionals, but a bit of statistics will allow astronomers to glean useful information.

True positives vs false positives in machine learning identification. Credit: Avirett-Mackenzie, et al

This new study takes a different approach. Rather than having experts train volunteers, they used experts to train machine learning algorithms. That’s easier said than done. Even the most skilled expert will occasionally make mistakes, or have certain biases, and any software trained on that expert will have the same biases. So the team partnered with the Big Data Applications for Black Hole Evolution Studies (BiD4BEST), which is an EU project that provides a training network for black hole evolution data. Together they used skilled experts to identify black hole mergers in both simulated data and data from the Sloan Digital Sky Survey (SDSS). By comparing the two, the team could remove biases from the machine learning data. The result was pretty successful. When algorithm sortings were compared to simulated mergers they found it had an accuracy of well over 80%, comparable to that of the most skilled experts.

The team then used the software to identify more than 8,000 active black holes and found an interesting connection between the growth of black holes and their galaxies. It isn’t galactic mergers that trigger the growth of supermassive black holes, but large quantities of nearby cold gas. The team found that mergers only drive rapid growth when they involve the merger of star-forming galaxies rich in gas and dust. Thus, the same conditions that lead to star formation also lead to supermassive black holes. This is part of the reason why galaxies and their black holes seem to grow in parallel.

As we continue to capture astronomical data at an almost exponential rate, software will be a necessary complement to skilled observers. As this study shows, the two can be used together effectively.

Reference: Avirett-Mackenzie, M. S., et al. “A post-merger enhancement only in star-forming Type 2 Seyfert galaxies: the deep learning view.” Monthly Notices of the Royal Astronomical Society 528.4 (2024): 6915-6933.

Like this:

Like Loading…

Categories
Technology

Dutch cybersecurity startup luggage €36M amid spike in on-line assaults

Dutch startup Eye Security has raised €36mn as it looks to defend European businesses from cyber criminals. 

Founded in 2020 by a group of Dutch intelligence and security experts, the Hague-based outfit provides cyber protection, incident response, and cyber insurance services to small-to-medium sized companies. 

The funding round, which brings Eye Security’s total amount raised so far to 57.5mn, was led by JPMorgan, the private investment arm of American financial giant JPMorgan Chase.

Eye Security plans to use the cash to consolidate its presence in the Netherlands, Germany, and Belgium. It also aims to expand into other European nations.

Eye Security’s founders: Piet Kerkhofs (left), Job Kuijpers (centre) and Vincent van de Ven. Credit: Eye Security

The <3 of EU tech

The latest rumblings from the EU tech scene, a story from our wise ol’ founder Boris, and some questionable AI art. It’s free, every week, in your inbox. Sign up now!

Key to its strategy is focusing on protecting smaller firms, which, it says, represent around 50% of all cybersecurity attacks but are the most vulnerable to their effects. Most don’t have the budget for an in-house cybersecurity team. 

“We’ve developed a scalable platform that not only strengthens a business’s defences against cyber threats but also quickly delivers insurance coverage,” said Job Kuijpers, the startup’s CEO, who was previously the director of the National Communications Security Agency for the Dutch intelligence service.  

Cybercrime scourge

Ransomware attacks (where cybercriminals hold someone’s data hostage until the victim pays for it back) saw a significant increase last year, according to data from the European Digital SME Alliance. For instance, last May saw 575 attacks in Europe, more than double the 223 recorded a year earlier.

The most prolific of these attackers was LockBit, an infamous Russian ransomware gang that was disrupted last month. Around 60% of small companies that are hacked by groups like these go out of business within six months, said Eye Security. 

Spikes in cybercrime have pushed EU regulators to take action. Europe’s Network and Information Security Directive (NISD) was updated last year, including more stringent reporting requirements for companies. From October 17, 2024, businesses who don’t report a hack risk a fine of up to €10mn or 2% of their annual revenue. 

The rule changes are leaving businesses scrambling to get their affairs in order. This, naturally, is good news for Eye Security. 

“We felt very strongly that companies deserved better. We also realised that there are not enough security specialists to help every company in Europe. We needed a radically different approach,” the company said on LinkedIn on Monday.

Categories
Health

Pfizer is betting large on most cancers medication after Covid decline

Nurphoto | Nurphoto | Getty Images

Pfizer is ready to move on from Covid. 

Now, the company is betting on cancer drugs to help it regain its footing after a rocky year marked by the rapid decline of its Covid business. It just might take a while before that bet pays off. 

Pfizer pitched its deeper push into oncology during a four-hour investor event last week. And it had a splashy 60-second Super Bowl ad that touted its initiative to “outdo cancer.” 

The shift comes at a crucial time for Pfizer. The pharmaceutical giant has been trying to shore up investor sentiment after its shares fell more than 40% in 2023. That share drop erased more than $100 billion in Pfizer’s market value.

Along with plummeting demand for its Covid products, Pfizer disappointed Wall Street last year with the underwhelming launch of a new RSV shot, a twice-daily weight loss pill that fell short in clinical trials and a 2024 forecast that missed expectations. The company has launched a $4 billion cost-cutting program, laying off hundreds of employees and shaving down its research and development spending. 

During the investor day, Pfizer laid out its priorities now that it has fully integrated with the targeted cancer drugmaker Seagen. That $43 billion Seagen acquisition doubled Pfizer’s oncology drug pipeline to 60 different experimental programs. 

With Seagen under its belt, Pfizer says its drug pipeline could produce at least eight blockbuster medicines by 2030, up from just five today. But the company did not disclose which drugs it believes could offer that potential. 

Some analysts noted that it might take a few years for some of Pfizer’s cancer drugs in mid-stage development to show pivotal clinical trial data and become less risky. 

Pfizer’s existing oncology portfolio is also facing some competitive pressure. Revenue from the blockbuster breast cancer drug Ibrance and prostate cancer treatment Xtandi, which Pfizer shares with Astellas Pharma, has declined over the past year. Both drugs are expected to lose market exclusivity in 2027. 

Still, some analysts came out of the investor day feeling encouraged. 

“The company is facing a number of challenges, but we believe the event was a success in laying out a path for the oncology business to help offset upcoming patent losses, and drive growth in the future,” Guggenheim analysts wrote in a note Tuesday. 

Long-term commercial strategy

Pfizer used the investor event to formally introduce its new business division dedicated to cancer research and to lay out a long-term strategy for it through the end of the decade.

That oncology unit hosts a sprawling portfolio of experimental medicines that Pfizer and Seagen discovered or acquired through deals, as well as the treatments both companies have long been selling. 

The unit is led by Chris Boshoff, a longtime Pfizer executive who most recently served as the company’s head of cancer research and development. 

“As a newly combined organization, our expertise and collective capabilities are now amplified to deliver even more impact for patients than each company could do by itself,” Boshoff said last week to kick off the event.  

Boshoff highlighted the scale of Pfizer’s capabilities, noting it has 10 manufacturing sites producing cancer drugs on three continents, while Seagen had just one. He also pointed to Pfizer’s commercial presence in more than 100 countries and a customer-facing commercial team that is triple the size of Seagen’s. 

Pfizer did not provide a specific sales projection for its oncology franchise by 2030. But the company said it expects roughly two-thirds of risk-adjusted oncology revenue to come from new drugs and new indications — or treatment uses — for existing products by the end of the decade.

Signage outside Seagen headquarters in Bothell, Washington, on Tuesday, March 14, 2023.

David Ryder | Bloomberg | Getty Images

Pfizer reiterated its expectation that the Seagen acquisition will bring in $10 billion in sales by 2030. 

But the company provided little guidance on what Seagen’s growth will look like until the end of the decade, UBS analyst Trung Huynh said in a note Thursday. 

A new focus 

Pfizer also highlighted a huge shift in its drug pipeline strategy. 

Boshoff said the oncology division plans to shift to biologic drugs as its main source of revenue, increasing the proportion of those treatments in its pipeline from 6% to 65% by 2030.

Biologics are treatments derived from living sources such as animals or humans, including vaccines, stem cell treatments and gene therapies. They are among the most expensive prescription drugs in the U.S.

Before the Seagen deal, 94% of Pfizer’s cancer products were small-molecule drugs. Those medicines are made of chemicals and have low molecular weights. 

Boshoff said biologics represent “a more durable revenue potential” based on several factors. That includes upcoming patent expirations and potential pressure from President Joe Biden’s Inflation Reduction Act. 

A provision of that law allows Medicare to start negotiating the prices of biologics as early as 13 years after they receive Food and Drug Administration approval, compared with just nine years for small-molecule drugs. The pharmaceutical industry has argued that would deter drugmakers from investing in small molecules.

Pfizer’s decision to rely more on biologics may also offer “better protection” against competition from cheaper copycats, Guggenheim analysts said in their note. Those copycats, or biosimilars, have historically had trouble gaining market share from biologic treatments. That’s unlike with drugs called generics, which are exact copies of small-molecule treatments. 

Small molecules will remain one of three core drug types of Pfizer’s oncology division. The other two are biologics, namely bispecific antibodies, and antibody-drug conjugates, or ADCs. 

Pfizer’s three core oncology drug types

  • Small-molecule drugs: Treatments with a low molecular weight made up of chemicals created in a lab. 
  • Bispecific antibodies: Treatments that can bind to two different antigens — or any substance that causes the body to have an immune response — at the same time. Those drugs are biologics because they are developed from living sources that produce antibodies.
  • Antibody-drug conjugates: Medications that deliver a cancer-killing therapy to specifically target and kill cancer cells and minimize damage to healthy ones. The treatments represent a hybrid between biologics and small-molecule drugs, but the FDA classifies ADCs as biologics.

Notably, the company is developing a “next-generation” platform for ADCs that combines Pfizer’s protein engineering and antibody design capabilities with Seagen’s ADC technology. Together, the companies have 12 ADCs in development, six of which are in early clinical trials or studies on animals.

JPMorgan analyst Chris Schott wrote in a note last week that the firm walked away from the investor event encouraged by the breadth of Pfizer’s mid-stage oncology pipeline. But he noted that it will take time before a number of the treatments show “pivotal data.”

Four core cancer types

Pfizer plans to focus on four main types of cancer: breast cancer; genitourinary cancer, which impacts urinary and genital organs or functions; thoracic cancer, such as lung, head and neck cancer; and hematology-oncology, or cancers of the blood, such as multiple myeloma and lymphomas. 

Pfizer expects breast cancer’s contribution to total oncology sales to drop to about 10% by 2030 from roughly 40% last year, the company’s oncology commercial chief Suneet Varma said during the event. 

That decline accounts for the upcoming loss of exclusivity of top-seller Ibrance, which raked in $4.75 billion in sales in 2023. 

But the company said it has a handful of breast cancer drugs in development that could become “potential growth drivers” as Ibrance sales fall. That includes a certain type of treatment called atirmociclib that could potentially be more effective and easier for patients to tolerate. 

Pfizer is testing the medicine as a second-line treatment for a certain type of breast cancer in a phase three trial. A second-line therapy is given when an initial treatment doesn’t work or stops working. 

The company also plans to start a separate late-stage trial on atirmociclib as a first treatment for the same condition in the second half of the year.

Pfizer expects genitourinary cancer to make up an estimated 35% of oncology sales by 2030, which would make it the largest franchise of the cancer business. That’s up from 20% in 2023. 

Pfizer is testing an experimental ADC called disitamab vedotin — which Seagen licensed from Chinese firm RemeGe — as a treatment for certain bladder cancers, with data from mid-stage and late-stage trials expected in 2025 and 2026.

Notably, RemeGe already sells that drug in China. Pfizer is also examining the medicine’s potential to treat breast cancer and other tumor types.

Meanwhile, Padcev, an ADC Pfizer shares with Astellas Pharma, in combination with Merck‘s immunotherapy Keytruda is becoming a new first-line standard of care for bladder cancer. Pfizer executives last week said Padcev had “mega-blockbuster” potential, which the company defines as raking in annual sales of more than $3 billion. 

Pfizer’s key cancer drugs on the U.S. market

  • Ibrance: treatment for certain breast cancers.
  • Xtandi: treatment for four types of advanced prostate cancer.
  • Adcetris: treatment for certain lymphomas from Seagen.
  • Padcev: treatment for some types of advanced bladder cancer, either alone or in combination with Keytruda.
  • Elrexfio: treatment for certain adults with multiple myeloma.
  • Talzenna: treatment for some breast cancers.
  • Lorbrena: treatment for a type of non-small cell lung cancer.

Pfizer executives expect thoracic cancer to double its revenue contributions by 2030. 

Seagen brings an ADC called sigvotatug vedotin to this franchise. The drug recently entered a late-stage trial as a second-line treatment for a certain type of lung cancer, with data expected around 2026 to 2027. Pfizer also plans to test the ADC as a first-line treatment.

Guggenheim analysts said they expect the treatment to be one of Pfizer’s blockbuster oncology drugs by the end of the decade. Those analysts also expect a bispecific drug called Elrexfio, which falls under Pfizer’s hematology-oncology portfolio, to eventually become a top seller.

The hematology-oncology franchise is expected to account for 25% of the cancer unit’s sales by 2030, up from just 10% in 2023. 

The FDA has approved Elrexfio for patients with multiple myeloma who have tried at least four prior types of therapy. But Pfizer is conducting two late-stage clinical trials on Elrexfio as a second-line treatment, with data not expected until around 2025 and 2026. 

Drugs outside of cancer

Pfizer is splitting the rest of its business outside of oncology into two divisions: a U.S. commercial unit and an international commercial unit. Those divisions are focusing on vaccines, along with metabolic and inflammatory conditions. 

This fall, Pfizer plans to roll out another updated version of its Covid vaccine that will target a new strain of the virus. 

The company previously outlined plans to develop “next-generation” versions of its Covid shot, which aim to broaden and extend the protection people get to a full year. 

But Pfizer hasn’t decided whether to move forward with those plans because the company needs to be convinced that there is still an “eagerness to embrace Covid intervention,” Dr. Mikael Dolsten, the company’s chief scientific officer, told CNBC in an interview last week.

The new vaccine COMIRNATY® (Covid-19 vaccine, mRNA) by Pfizer, available at CVS Pharmacy in Eagle Rock, California.

Irfan Khan | Los Angeles Times | Getty Images

Dolsten pointed to two other “strong pillars” in the company’s vaccine portfolio: bacterial and viral shots. The company is testing a “fourth-generation” version of its vaccine to prevent pneumococcal disease, which is caused by a bacteria that can attack different parts of the body.

Pfizer is also working to expand the use of its shot against respiratory syncytial virus, commonly called RSV, to high-risk patients ages 18 to 59. It’s currently approved in the U.S. for expectant mothers and adults age 60 and above. 

The company is also testing combination vaccines targeting multiple respiratory viruses, including a shot for Covid and the flu in late-stage development.

Outside of vaccines, the company is developing an oral treatment for sickle cell disease called GBT601. Pfizer views that drug as a potentially more effective successor to its drug Oxbryta, which is already approved for the condition.

Pfizer also expects to release mid-stage trial data on its experimental treatment for cancer cachexia, or what Dolsten called “the opposite of obesity.” It refers to the loss of body weight and muscle mass, along with weakness that may occur in patients with cancer, AIDS or other chronic diseases.

Another area that’s top of mind for investors is obesity. Pfizer expects to release early-stage trial data on a once-daily version of its experimental weight loss pill, danuglipron, in the first half of the year. The company is also working on a second drug for obesity, but has not disclosed how it will work. 

Dolsten touted the potential of a weight-loss drug pill, which could help meet the soaring demand for obesity treatments. Much of the existing injectable drugs for the condition are in shortage in the U.S. He also noted that a pill would likely be priced differently than injections, which cost around $1,000 per month before insurance. 

“A pill would allow you also to have more access,” Dolsten said. “If you have 300 million patients per year, it will be one of the biggest medications ever.”

Categories
Science

Hudson Bay polar bears now thought-about more than likely to outlive future sea ice loss – Watts Up With That?

From Polar Bear Science

Susan Crockford

Over the last 10 years, Hudson Bay polar bears have morphed from being the “most at risk” across the Arctic to the “least at risk.” Who would have thought?

That’s probably because the experts now have to admit that polar bear numbers have not declined since 2004 and bears have been in good body condition since at least 2016. Southern Hudson Bay bears have apparently increased in number since 2016. How ironic is it that the photo above, taken in Hudson Bay — the only Arctic region where trees grow — was used to illustrate a recent Mother Jones article promoting a new prediction of future Arctic summer sea ice loss that’s said to pose a threat to polar bear survival.

Here is a brief retrospective of predictions for survival of Western Hudson Bay polar bears (based on predictions of future sea ice loss), my emphasis throughout:

2013

In 2013, Andrew Derocher told The Guardian (27 November):

“All indications are that this population could collapse in the space of a year or two if conditions got bad enough,” said Andrew Derocher, a polar bear scientist at the University of Alberta.

“In 2020, I think it is still an open bet that we are going to have polar bears in western Hudson Bay.”

Contrary to this prediction, sea ice conditions over Western Hudson Bay haven’t changed since about 1998: most years, the ice-free season has been about 3 weeks longer than it was in the 1980s. Summer sea ice conditions are not getting worse.

2016

In 2016, seal biologist Steve Ferguson told the Winnipeg Free Press (6 December):

Hudson Bay could experience its first ice-free winter within five to 10 years, Ferguson said.

“I don’t think polar bears and seals will be able to adapt. I think they’ll just die out in places like Hudson Bay. There’s little to stop the trend in loss of sea ice, even if we stop producing greenhouse gasses,” he said.

Contrary to this dire prediction, Hudson Bay has been no where near to ice-free in winter, see the sea ice development chart below showing ice thickness for the week of 4 March 2024:

2024

Steven Amstrup told the Winnipeg Free Press in 2024 (28 February) the following about Western Hudson Bay polar bears, seemingly in direct contradiction to a paper he co-authored last year:

Even so, the population seems to be faring better than the rest of the world, Amstrup said during his presentation.

“If there’s a likelihood of being able to save bears anywhere, it’s probably in (the) Hudson Bay,” he said.

The rate of decline in sea ice is lower in the western and southern portions of the Hudson Bay than anywhere else globally, Amstrup relayed.

This prediction seems like a clear admission that previous predictions were wrong. This means that any of the models that formerly used WH bears as a proxy to predict the survival of all other subpopulations, including the one published last year, are not worth the paper they were printed on. What a surprise!

Like this:

Like Loading…

Categories
Entertainment

Relationship? Drake and Latto’s Lil Sis Noticed Leaving Restaurant

Drake and rapper Latto’s younger sister, Brooklyn Nikole, were stopped leaving a restaurant, sparking dating rumors.

According to Complex, the Atlanta lyricist’s little sis was seen on Friday night with the ‘Spin Bout You’ rapper.

RELATED: Issa Bae Watch?! Social Media Speculates 21 Savage Also Has Latto’s First Name Tattooed (PHOTOS)

Are Drake and Brooklyn Dating?

The two were accompanied by friends as they exited a restaurant. There was no PDA displayed. Watch the video below

CANDID CAMERA 📸 | Drake spotted out and about with Latto’s little sister Brooklyn Nikole. 👀 pic.twitter.com/EFgof4OSYq

— KenBarbie™ (@itsKenBarbie) March 9, 2024

Social media pointed out the significant age gap. Drake is 16 years older than the beauty entrepreneur. Brooklyn just gained the legal right to drink at 21-years-old. While Adonis’ dad is 37. The Canadian rapper is known for dating younger women.

Social media sleuths purport Drake was referring to Brookie on his verse for 4batz’s “Act II: Date @ 8 (Remix). He mentions the area where she were raised in Georgia, Complex reports.

“How you get all of that body and face, though? / What kinda water they servin’ in Clayco?,” Drizzy spit.

How Did They Meet?

It is possible that Drake and Brooklyn met when she attended his ‘It’s All A Blur Tour‘ stop last September with Latto. After all, 21 Savage was also a headliner at the time. However, it is unclear where the entertainer and the beauty mogul in the making met. Latto has been rumored to be dating 21 Savage, so they have likely ran into each other a number of times.

Fans also highlighted the rumored romance could cause his relationship with label mate Nicki Minaj to crumble again. They mended their relationship in 2021 after a falling out. Though Latto and Nicki have had public spats, fans speculate Drake dating Brooklyn may seemingly muddy where his loyalty lies.

Neither have confirmed the hook up, so the two could just be homies.

Men and women can just be friends, right?

RELATED: Blow A Bag, Then! Drake Is Trending After Sexyy Red Details The Lavish Gifts He Recently Got Her (WATCH)

Categories
Sport

Switch Discuss: Barca dealt blow in race for Bayern star Kimmich

  • Nick Judd, Transfer writerMar 10, 2024, 08:15 PM ET

We still have some time before the summer transfer window reopens in Europe, but there are plenty of moves in the works and gossip swirling around. Transfer Talk brings you all the latest buzz on rumours, comings, goings and, of course, done deals!

TOP STORY: Bayern hopeful of keeping Kimmich

Barcelona’s hopes of signing Joshua Kimmich have taken a hit, with Bayern Munich ready to begin talks with the 29-year-old over a new contract, reports Mundo Deportivo.

Editor’s Picks

2 Related

The midfielder has been a long-term target for Barca, though the Spanish club are hamstrung by their ongoing financial issues. However, with the player openly expressing his frustrations with Bayern boss Thomas Tuchel, combined with the way the season has panned out for Bayern — with the reigning champions looking increasingly likely to finish second Bayer Leverkusen — whispers over a departure for Kimmich had intensified into a roar.

However, new Bayern sports manager Max Eberl reportedly believes that the situation between the Germany internation and the club will improve now that Bayern have confirmed that Tuchel will be leaving at end of the season.

Kimmich, whose contract ends in 2025, has also been linked to the likes of Manchester City and Manchester United.

– Stream on ESPN+: LaLiga, Bundesliga, more (U.S.)

Bayern Munich are reportedly hoping that changing their head coach will convince Joshua Kimmich to stay at the club. (Photo by Sebastian Widmann/Getty Images)

PAPER GOSSIP

– Chelsea boss Mauricio Pochettino has admitted on several occasions that he wants to keep midfielder Conor Gallagher, but the club remains likely to fast-track his departure to help stave off Financial Fair Play issues. That’s according to Teamtalk, which believes that the Londoners will look to move Gallagher off the books before June 30.

– AC Milan are hoping to persuade their rising star Francesco Camarda to sign his first professional contract with them, but the Rossoneri face huge pressure from Paris Saint-Germain, among others. Footmercato reports the French side are among a number of clubs tracking the 16-year-old striker who has so far scored nearly 500 goals in under 90 matches for Milan’s various age groups.

– Lazio failed in their attempt to sign Jack Clarke from Sunderland in January, but the Italians are hoping for better luck in their pursuit of the winger, along with his teammate Jobe Bellingham, in the summer, according to Corriere dello Sport. Sunderland were reluctant to let 23-year-old Clarke leave for Italy in the winter transfer window, and it’s easy to see why; for the winger has scored 15 goals and added four assists in 33 Championship matches this season.

– Five European clubs have been tracking highly rated Tottenham Hotspur youngster Callum Olusesi, but Fabrizio Romano reports that the 16-year-old is set to sign a new professional contract with the north London club. Tottenham were aware of interest from a number of clubs last summer, but they’re now confident of keeping the teenager for two more years at least, with the Nigerian set to sign a deal on Monday that would keep him at the club until June 2026.

Categories
Health

I realized how consuming and train affect my blood sugar

Ashley Capoot wearing a CGM.

Ashley Capoot | CNBC

As it turns out, exercise is good for you. So is sleep, and unfortunately, so are vegetables. 

I’ve heard these health adages hundreds of times before, but they truly began to hit home for me this winter as I tested out a metabolic health platform from the startup Signos. In short, the company offers a subscription service that includes a small continuous glucose monitor (CGM), which you stick on your arm or abdomen, that sends that data to the Signos app which, in turn, aims to help you lose weight by keeping track of your blood sugar.

The subscription price varies depending on the plan you pick. A one-month plan starts at $449, but a 6-month plan starts at about $143 a month if you pay upfront. But services like this, once reserved for diabetics, may soon offer a whole new revenue stream for health companies. Dexcom, for example, recently received FDA clearance for its over-the-counter Stelo product, expected to launch this summer. Meanwhile, Signos competes with other firms like NutriSense, Veri and Levels.

I wanted to get a first-hand understanding of what these glucose monitors are like, so I gave Signos’ latest system, which uses a Dexcom G7 monitor, a try. Here’s what I learned.

Signos

Founded in 2018, Signos uses continuous glucose monitors, or CGMs, and an artificial intelligence-powered app to help people better understand their metabolisms. The company gives users personalized insights into how their bodies respond to specific foods and when they should exercise to get the best results for weight loss. 

Glucose is a type of sugar we receive from food, and it’s the body’s main source of energy. A CGM is a small sensor that pokes through the skin to track an individual’s blood glucose levels, or blood sugar levels, in real-time. The sensor is usually worn on the upper arm or abdomen, and it can wirelessly transmit data to a smartphone. 

CGMs are primarily used by people with diabetes since they can help patients get alerted to emergencies. But Signos’ CGM system is meant for average consumers, so it is not intended for diabetes management. Other companies like Abbott Laboratories are also launching consumer-facing CGM systems in the U.S. this year. 

Signos’ platform teaches users how their daily habits like diet, hydration, exercise, stress and sleep affect their glucose and can cause it to spike. 

Glucose spikes occur when the amount of sugar present in the bloodstream rapidly increases. This often happens after eating. In the short term, spikes can cause feelings of lethargy and fatigue, but high blood sugar can lead to more serious health problems like diabetes, heart disease and kidney disease over time, according to the Centers for Disease Control and Prevention. 

Everyone’s glucose levels are variable, so spikes and dips are inevitable, but Signos aims to help people reduce the intensity and frequency of their spikes. The company says that maintaining relatively stable glucose levels can help people improve the health of their metabolism, lose weight and ultimately reduce the risk of chronic disease. 

Getting set up

Woman with Signos wearable and app

Source: Signos

To get started with Signos, I had to take a quick questionnaire that asked me for some basic biological information and details about my medical history. I submitted my answers for review by an independent physician, and my CGM prescription was approved and began processing for shipment a few hours later.

After a couple of days, my kit arrived in a brown Signos box. It includes an instruction manual, the CGMs, alcohol wipes and athletic patches to put over the CGM once it’s applied. I followed the instructions in the manual and downloaded the Signos app, which prompted me to set up accounts with Signos and the CGM company Dexcom

Dexcom makes the CGMs that Signos uses, though Dexcom’s products are exclusively designed for patients diagnosed with diabetes. Signos is using Dexcom’s CGMs as part of a clinical study approved by an institutional review board designated by the U.S. Food and Drug Administration, which monitors biomedical research involving real people, Sharam Fouladgar-Mercer, Signos’ co-founder and CEO, told CNBC in October. 

Dexcom Ventures also backs Signos as an investor, and the firm participated in the $20 million funding round that Signos announced last fall.  

Signos’ platform works with Dexcom’s G6 CGM and the newer G7 CGM. I tested the platform using the G7, which Signos launched in January. The G6 and the G7 sensors last for 10 days, and I went through three G7s during my trial. 

Ashley Capoot wearing a CGM.

Ashley Capoot | CNBC

Once I had set up my accounts, it was time to put on my first sensor, which I was nervous about.

I’m generally fine around needles, though I tend to look away if I have to get a shot at the doctor’s office. The CGM’s needle is small – it looks like someone clicked a mechanical pencil a few times, for comparison – but I can’t say I was excited to stick it into my arm. 

Much to my relief, applying the sensor is easy and painless.

The Signos app walked me through the process step by step, offering a one-minute video and a series of GIFs I could watch. I cleaned the back of my left arm with an alcohol wipe, placed the applicator there, pressed the button on the applicator and popped the CGM, needle and all, right onto my arm. The G7 is white, about the size of a quarter, and maybe half an inch thick.  

I paired the CGM to the Signos app by enabling Bluetooth and scanning the corresponding QR code on my applicator. Once the CGM was applied and paired to my app, I put a purple athletic patch on top to help protect the sensor from tugging, sweat and water. 

It took the sensor about 30 minutes to adjust to my body before it was warmed up and ready to go.

What’s good

I was worried that the CGM would be painful or cumbersome, but I forgot about it often, and it’s easy to wear normal clothes and jackets over it, even if they have tight sleeves. 

I experienced some sensitivity for a couple days when sleeping on my left side, particularly after changing out the sensor. My upper arm felt a little tender, like there was a light bruise. However, I chose to wear the CGM in the same place on my left arm each time, and I think I could have avoided that sensitivity if I had switched between my left arm and my right arm.

I had never seen or interpreted glucose data before, and I thought the Signos platform did a nice job explaining concepts and breaking them down. The app led me through a series of short articles and activities to get started, like how to log my meals and exercise. 

It also introduced me to the concept of my “optimal glucose range,” which is where Signos wants you to try and keep your glucose levels. Signos starts by setting the upper bound of the range at 120 mg/dL, and the lower bound at 80 mg/dL, but the app’s algorithm adjusts it based on your body’s patterns. My upper bound was eventually adjusted to 126 mg/dL, for instance. 

When you look at the Signos home page, you can see your real-time glucose reading, your glucose level graph (which includes a shaded area to indicate your optimal range), and the percentage of time you’ve spent in the range each day. This could be particularly beneficial for folks who may be prediabetic and want to keep an eye on their levels over time.

Once I got the hang of the basics, Signos prompted me with more activities and articles that helped me experiment and deepen my understanding of my blood sugar. For instance, one activity encouraged me to try exercising right after a meal, and when I did, I saw it drastically reduced the spike I was experiencing. 

Another activity had me try and guess what I thought my glucose levels were at different points throughout the day. I was surprised how quickly I began to understand the correlation between how I was feeling and my current reading. You can skip activities if you don’t want to do them, but on the whole, I found them interesting and useful.  

Signos also has registered dieticians on staff, and users can ask them questions via chat, email or through a phone consultation. I set up a meeting after my first week wearing a CGM, and I found it very helpful. I asked a bunch of questions about my data and the Signos app itself, and I also got some tips about what to try and work on next.

Zoom In IconArrows pointing outwards

I knew the experience would be personalized, but I don’t think I’ve ever had this much specific insight into what is happening in my body. I found it fascinating to see how I responded to different foods, and there were some surprises.

I frequently eat instant oatmeal for breakfast, for example, and have always thought of it as a relatively healthy meal. But in actuality, I learned oatmeal causes my glucose to spike significantly. On Feb. 9, oatmeal raised my levels from 88 mg/dL to 167 mg/dL. So while it may be a great breakfast for some people, oatmeal isn’t necessarily the best choice for me. 

I was less surprised by my reactions to many other foods, but I still found it valuable to reinforce these concepts with data. Processed foods like chips and sweets caused large spikes in my levels, but fruits, vegetables and protein-rich meals had a much more gradual impact. I eat greek yogurt as a snack a lot, for instance, and I found that it hardly caused my levels to spike.  

It felt powerful to see how my body responded to nutritious food and it definitely made me more conscious of the choices I was making.   

Ashley Capoot wearing a CGM.

Ashley Capoot | CNBC

As it turns out, spikes in your blood sugar can be caused by a whole lot more than just food. That was news to me. In addition to logging meals and exercise, the Signos app has a “Tags” feature where you can write notes and select from a list of more than 60 different possible spike-causing culprits. Some of the options include stress, travel, medication, sickness, crying and even a hot shower. 

I learned that my glucose tends to spike while I’m writing a breaking news story (who knew!), and I spend less time in my optimal range when I’m feeling tired. I had a particularly stressful week at work in January, and looking back at my readings, I can definitely tell. 

I found it helpful to visualize how all sorts of different factors, some within my control and some not, could impact my blood sugar. It really drives home the idea that you are affected by the world around you.     

And for bonus points, the CGM is a great conversation starter. 

I found that my friends, family and colleagues were really interested in the device and what I was learning from it. Since it’s not all that common for the average person to wear CGMs yet, I think there was an element of novelty there. 

Finally, it’s easy to take off the CGM when it expires. After the 10 days are up, you simply grab the adhesive and peel it off like a sticker.  

What’s bad

Signos’ user interface is easy to use, but some features were more intuitive than others. 

It took me a few days to learn how to input my sleep, for instance, because I couldn’t figure out how to log the hours correctly. It was also hard to gauge how much detail to use when logging my meals, as I tended to keep my entries to just a few words. I might have gotten more specific insights and fine-tuned my algorithm further if I had more guidance there. 

Additionally, it wasn’t always possible for me to engage with the platform’s alerts and activities, particularly during the work day. 

After eating a meal, I would often get a “Fast Rise” notification from my Signos app, which indicates that a glucose spike is occurring. The notification encourages users to engage in 20 to 30 minutes of “brisk walking” or 10 to 15 minutes of plyometrics, a form of high-intensity exercise, to help reduce the spike. I work in-person at CNBC’s newsroom three days a week, so this often wasn’t realistic for me to do. 

I asked about this notification when I met with the Signos dietitian, and she told me that any movement is beneficial, even if it’s just a quick walk up or down a flight of stairs. I tried to make sure to take a lap around the newsroom once I learned that, but I think it would have been helpful to know upfront, too. 

Zoom In IconArrows pointing outwards

A “Fast Rise” notification on Signos.

Subscriptions to Signos are expensive, and for many users, CGMs are not covered by insurance yet. Customers who sign up for Signos can choose a one-month, three-month or six-month plan.

The steep price tag is definitely worth considering. According to its website, Signos said users who have been diagnosed with type 2 diabetes may be able to get the cost of the CGM covered by their insurer. But users who do not have type 2 diabetes may be out of luck. 

The company said some people may be able to use their Health Savings Account reimbursement funds to cover the Signos, but that it “is not responsible for reimbursement in any capacity,” according to the site.  

In other words, users who want to try and reduce the costs of the platform have to try and figure it out themselves. 

I also found myself checking the Signos app frequently, almost like it became another form of social media. This gave me some pause. 

I have been fortunate to have had a relatively positive relationship with food throughout my life, and I’m also not someone who experiences much health anxiety. Even so, I tried to be very conscious of my mindset and attitude toward the Signos platform. I treated Signos like a tool and a learning experience, and I really didn’t want to put too much emphasis on the numbers. 

I knew that approach would be best for me, and it worked well for the most part. However, I did catch myself feeling guilty about large spikes on a few occasions. 

As I noticed those feelings, and how often I was checking the app, I felt like it was pretty easy to see how the platform could end up being harmful for some users’ mental health, particularly if they’ve struggled with body image or eating disorders. 

Signos said all prospective members are asked about their medical history, including disordered eating, in their initial medical questionnaire. If someone is actively experiencing or in recovery from an eating disorder, Signos said the independent physician would not approve them for participation in the Signos program.

The company said it does not recommend any specific eating style, and there are metabolic health coaches on staff to help check in with users about how they feel. 

As with most things, I think trusting yourself is key here. If you don’t think accessing your metabolic data would be good for your mental health, then using a CGM is probably not a great idea. You can also always check in with your doctor to decide if the technology is right for you. 

Takeaways

The Signos experience really depends on you, the user. 

The app isn’t going to do the learning or make lifestyle changes for you, so if you aren’t willing to take the time to log your meals and complete activities, chances are you won’t get much out of the platform. 

As a young and relatively healthy individual, I wasn’t sure what to expect from Signos, but I learned a lot about how my body responds to my diet, sleep, exercise and stress. The CGM is like a little window into what goes on beneath the skin, and I think it’s easy to see why it’s a valuable tool. After just one month of use, I have a deeper understanding of why I feel sleepy, lethargic or energized.

I wouldn’t be surprised if I return to CGM systems at different stages of my life to better understand how I am responding to my nutrition and the world around me.  

Categories
Science

This Scorching Jupiter is Doomed to Crash Into its Star in Simply Three Million Years

In 2008, astronomers with the SuperWASP survey spotted WASP-12b as it transited in front of its star. At the time, it was part of a new class of exoplanets (“Hot Jupiters”) discovered a little more than a decade before. However, subsequent observations revealed that WASP-12b was the first Hot Jupiter observed that orbits so closely to its parent star that it has become deformed. While several plausible scenarios have been suggested to explain these observations, a widely accepted theory is that the planet is being pulled apart as it slowly falls into its star.

Based on the observed rate of “tidal decay,” astronomers estimate that WASP-12b will fall into its parent star in about ten million years. In a recent study, astronomers with The Asiago Search for Transit Timing Variations of Exoplanets (TASTE) project presented an analysis that combines new spectral data from the La Silla Observatory with 12 years worth of unpublished transit light curves and archival data. Their results are consistent with previous observations that suggest WASP-12b is rapidly undergoing tidal dissipation and will be consumed by its star.

Their results were published in a paper titled “TASTE V. A new ground-based investigation of orbital decay in the ultra-hot Jupiter WASP-12b” that appeared on February 21st in the journal Astronomy & Astrophysics. The paper is the fifth in a series published by the TASTE project, a collaborative effort involving astronomers and astrophysicists from the National Institute of Astrophysics (INAF), the “Giuseppe Colombo” University Center for Space Studies and Activities (CISAS), and multiple Italian universities and observatories.

Artist’s impression of WASP-12b, a Hot Jupiter deformed by its close orbit to its star. Credit: NASA

WASP-12b was one of many Hot Jupiters discovered by the Wide Angle Search for Planets (WASP), an international consortium funded and operated by Warwick University and Keele University. In terms of exoplanet discoveries, WASP was second only to the Kepler mission and also relied on the Transit Method. This consists of monitoring stars for periodic dips in luminosity to infer the presence of planets and to constrain their size and orbital periods. Based on their observations of its F-type (yellow-white dwarf), the WASP survey determined it was a gas giant 1.465 times as massive as Jupiter with an orbital period of 1.1 days.

Pietro Leonardi, a PhD Student in Space science and technology at the Università di Trento was the lead author on the paper. As he told Universe Today via email, the discovery of Hot Jupiters (HJ) represented a major breakthrough in exoplanet studies:

“The first discovery of an exoplanet around a Solar-type star by Mayor & Queloz (1995) completely revolutionized how we thought planets should and could be found orbiting a star. As human beings, we often have a tendency to envision new concepts close to those we already understand. This cognitive bias is equally applicable to scientists, who are, after all, ordinary individuals.

“Until 1995, it was widely assumed that exoplanets—planets orbiting stars beyond our solar system—would resemble those in our own solar system. We expected to find large, gaseous giants like Jupiter, Saturn, Uranus, and Neptune residing at significant distances from their host stars, while smaller, rocky planets like Mercury, Venus, Earth, and Mars would occupy the inner regions.”

Astronomers have found another hot Jupiter in a polar orbit around its star. This illustration shows the exoplanet WASP-79 b following a polar orbit around its star. Credit: NASA/GSFC

The discovery of a massive gas giant orbiting very closely to its star shattered these expectations and forced astronomers to reevaluate their theories on planet formation and evolution. For instance, scientists had long held that exoplanet systems likely resembled the Solar System and that their planets formed close to where they orbited. In this scenario, rocky planets form closer to their suns while gas giants form in the outer reaches beyond the “Frost Line” – the boundary beyond which volatile elements (hydrogen, carbon, nitrogen, and oxygen) begin to freeze.

“It highlighted the fact that our Solar System is not representative of the typical planetary system in the universe; rather, it appears to be an outlier,” said Leonardi. However, WASP-12b stood apart from other HJs in that it was the only one that appeared to be experiencing variations in its orbit. Multiple scenarios were proposed for this, including the possibility that it was experiencing tidal decay (slowly falling into its star). As Leonardi explained:

“WASP-12b is a very extreme planet. It is indeed part of the sub-category called Ultra-hot Jupiters. The planet is very close to its host star, orbiting it in just 1.09 days and having a surface temperature of 2600 K. Due to its extreme vicinity to its host star, the planet feels a strong gravitational pull that strips part of its atmosphere of heavy metals, which create a disk around the star. When it was first discovered that WASP-12b had a changing orbit, the other explanations that were explored were the Rømer effect and Apsidal precession.”

In the former scenario, the timing variation was attributed to the star being closer to Earth in the direction of the line of sight. In the latter, it was due to a gradual rotation of the planet’s orbit. For their study, Leonardi and his colleagues presented a new analysis based on 28 previously unpublished transit light curves gathered by the Asiago Observatory between 2010 and 2022. This was combined with all the available archival data and updated high-resolution spectra obtained by the High Accuracy Radial Velocity Planet Searcher-North (HARPS-N) instrument on the ESO 3.6-meter telescope at the La Silla Observatory.

An artist’s conception of the hot Jupiter WASP-79b. Credit: NASA)

These observations allowed the team to confirm that the planet’s orbit is decaying and that its star will consume it sooner than expected – in 3 million years rather than ten. These results have effectively settled the debate about this planet’s peculiar orbit and present opportunities for follow-up studies. Said Leonardi:

“This study helps us to get closer to understanding the rare scenario of orbital tidal decay and gives us a perfect laboratory to study the star-planet interactions. The system is still yet to be uncovered in various aspects, for example we still need to understand how this fast tidal dissipation is possible. According to our theories the tidal dissipation we observe should not be possible in a star still in the main sequence. However, our precise stellar parameters inferred from the HARPS@TNG spectra confirm that the star is still in the main sequence.”

In the past thirty years, the field of exoplanet studies has experienced tremendous and accelerating growth. With more than 5,000 confirmed exoplanets available for study, the field is now transitioning from discovery to characterization. The more we learn about worlds beyond our Solar System, the more we can infer about the nature of planets in our Universe and how they form and evolve with time. Someday, this could lead to a new understanding of the nature of life itself and what conditions under which it can arise.

Further Reading: arXiv

Like this:

Like Loading…